If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
reembolso del 75% del coste de Búsquedas e Informes Tecnológicos de Patentes. Más información*
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
104
results.
Updated on
19/05/2024 [07:24:00]
Absstract of: US2024156129A1
Methods of preventing or decreasing PEDv and/or Salmonella bacteria in animal feed, feed ingredients, and pet food are provided. The methods utilize generally safe chemical mitigants, such as medium chain fatty acids, essential oils, and sodium bisulfate. The chemical mitigants are introduced to the feed or feed ingredients at inclusion rates selected so as to prevent or decrease PEDv and/or Salmonella bacteria in the animal feed, feed ingredients, or pet rood. The methods are particularly suitable for use in post-processing treatment of animal feed, feed ingredients, or pet food that will be transported and stored for multiple days or weeks.
Absstract of: US2024156936A1
The present invention provides compositions and methods of inducing an immune response in a subject in need thereof, comprising administering to the subject an immunologically-effective amount of a live Salmonella typhi vector comprising a heterologous antigen from a pathogen, wherein the heterologous antigen comprises an outer membrane protein, an antigenic fragment thereof or a variant thereof, wherein the antigen is delivered to a mucosal tissue of the subject by an outer membrane vesicle.
Absstract of: US2024156788A1
In one aspect, the disclosure relates to compositions and methods for dispersing exiting Salmonella biofilms and inhibiting formation of Salmonella biofilms. In various aspects, the disclosed compositions can be used in methods of treating a persistent Salmonella infection, including an asymptomatic infection. Such infections can colonize a variety of tissues, including the gall-bladder. Also disclosed are methods of treating typhoid fever. Also disclosed are methods for mitigating or preventing secondary outbreaks of typhoid fever by treating asymptomatic subjects who had been symptomatic for typhoid fever at a previous time. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
Absstract of: US2024151719A1
A method and kit for for determining of an effective concentration of an antimicrobial agent for inhibiting bacterial growth are provided. The method and kit involve the use of a first and second multiwell receptacle. A fluid sample containing or suspected to contain one or more microbial organisms is dispensed into the wells of the first multiwell receptacle containing a range of dilutions of an antimicrobial agent, growth medium and a bacteriophage to form assay mixtures in the wells. The assay mixtures are then transferred to the corresponding wells of the second multiwell receptacle for detection.
Absstract of: CN117987337A
本发明公开了一种同时缺失spiC基因、purL基因、sifA基因、trmE基因、rfbE基因中的两种或两种以上的多基因缺失的肠炎沙门菌。本发明还公开了其上述多基因缺失的肠炎沙门菌在制备肠炎沙门菌灭活疫苗中的应用。本发明公开的五基因同时缺失的肠炎沙门菌减毒株毒力较野生型肠炎沙门菌显著下降，在宿主体内定殖时间明显缩短，接种后鸡只无不良反应，对强毒力肠炎沙门菌提供良好的保护作用，可有效清除强毒力菌株感染。应用于肠炎沙门菌灭活疫苗具有良好的免疫原性，可对雏鸡可提供坚实的免疫保护效果。
Absstract of: WO2024091038A1
The present invention relates to novel bacteriophages LBC1, LBC2, LEC1, LEC2, or LSE1 and, specifically, to the bacteriophages LBC1, LBC2, LEC1, LEC2, or LSE1 and uses thereof. The novel bacteriophages of the present invention have the capability to inhibit the growth or cause the death of Bacillus, Escherichia coli, or Salmonella and thus can be applied to antibiotics, disinfectants, cleaning agents, food additives, foods, feed additives, feeds, and pharmacological compositions for the prevention or treatment of infections caused by Bacillus, Escherichia coli, or Salmonella.
Absstract of: WO2024091122A1
The invention is directed to a method for providing a foodstuff preservative. More specifically, to a foodstuff preservative that inhibits growth of Escherichia, Salmonella and/or Listeria. The invention is further directed to a foodstuff preservative obtainable by the method. The invention is further related to a method for screening antimicrobial effects of a ferment, a method for providing a preserved foodstuff and the use of a foodstuff preservative.
Absstract of: US2024140996A1
A method for increase the presentation of ETEC CS6 antigen on a cell surface, comprising the step of contacting cells expressing said antigen with an aqueous solution comprising 0.6-2.2 percent phenol by weight, such that the presentation of said antigen is increased by at least 100%. A method for the manufacture of a killed whole cell vaccine for immunization against CS6-expressing ETEC. Cells and vaccines obtainable by the above methods.
Absstract of: EP4360461A1
The invention is directed to a method for providing a foodstuff preservative. More specifically, to a foodstuff preservative that inhibits growth of Escherichia, Salmonella and/or Listeria. The invention is further directed to a foodstuff preservative obtainable by the method. The invention is further related to a method for screening antimicrobial effects of a ferment, a method for providing a preserved foodstuff and the use of a foodstuff preservative.
Absstract of: AU2022343176A1
Provided herein is the ability for intravenous delivery of bacteria without the septic side-effects and for delivery of immune modulating proteins that are systemically toxic to be delivered directly to the tumor micro-environment without any systemic toxicity.
Absstract of: AU2022343176A1
Provided herein is the ability for intravenous delivery of bacteria without the septic side-effects and for delivery of immune modulating proteins that are systemically toxic to be delivered directly to the tumor micro-environment without any systemic toxicity.
Absstract of: MX2022000802A
The present invention relates, with respect to nonalcoholic fatty liver disease, to a kit for predicting or diagnosing the risk of the disease, a method for providing information for predicting or diagnosing the risk of the disease, a method for screening a therapeutic agent for the disease, and a pharmaceutical composition for prevention or treatment of the disease. Specifically, the present invention can effectively predict or diagnose the risk of nonalcoholic fatty liver disease and, in particular, has superior significance in prediction and information provision for non-obese subjects. Accordingly, the present invention can be effectively used in the prevention or treatment of the disease by providing effective information on nonalcoholic fatty liver disease. In addition, the pharmaceutical composition for prevention or treatment can be effectively used in the treatment of nonalcoholic fatty liver disease.
Absstract of: WO2024079358A1
The present invention relates to a modified live attenuated Gram-negative bacteria, wherein said bacteria has been modified in such a way that RNA molecules can be safely and efficiently delivered to target eukaryotic cells. As such, the present invention relates a to a bacterial delivery system and various uses and methods thereof.
Absstract of: WO2024081871A1
Technologies for the prevention and/or treatment of Shigella infections.
Absstract of: CN117887745A
本发明属于生物技术领域，公开了了一种沙门菌鞭毛蛋白FimH的制备及其在Elisa检测中的应用，本FimH蛋白是沙门菌的鞭毛，通过原核表达系统大肠杆菌BL21(DE3)进行表达，接着按照不可溶蛋白的处理方法进行亲和层析纯化，变性，再复性；并对所制备的蛋白用Bradford试剂盒进行浓度的测定。最后将获得的蛋白作为Elisa检测板的包被抗原。本发明中蛋白的制备方法简单，成本低，容易大批量制备，可应用于ELISA检测方法中，应用前景好。
Absstract of: WO2024074554A1
The present invention relates to compositions and methods for treating or preventing infections, in particular infections by intracellular parasites such as Cryptosporidium spp. The present invention also relates to compositions and methods for treating or preventing viral or bacterial infections, in particular intestinal infections such as those caused by rotavirus and Salmonella spp. Infections. The methods comprise administration of, and the compositions comprise, a farnesyl-diphosphate farnesyltransferase 1 (FDFT1) inhibitor, such as lapaquistat.
Absstract of: WO2024077197A1
A method, composition and kit for determining the presence or absence of Salmonella sp., Shigella sp./Enteroinvasive Escherichia coli (EIEC), and Campylobacter sp. in a sample, comprising producing an amplicon by subjecting a reaction mixture including the sample and five primer pairs to reaction conditions suitable to amplify targeted nucleic acids. The five primer pairs include primer pair A that specifically hybridizes with a portion of Campylobacter coli genome, primer pair B that specifically hybridizes with a portion of Campylobacter jejuni genome, primer pair C that specifically hybridizes with a portion of Campylobacter upsaliensis genome, primer pair D that specifically hybridizes with a portion of Salmonella sp. genome, and primer pair E that specifically hybridizes with a portion of Shigella sp./EIEC genome; and determining the presence or absence of Campylobacter sp., Salmonella sp., and/or Shigella sp./Enteroinvasive Escherichia coli (EIEC) in the sample based on the amplicon.
Absstract of: US2024115671A1
Provided herein is a bacterial delivery platform that harnesses mechanisms unique to Salmonella to intracellularly deliver protein-based drugs.
Absstract of: AU2022343176A1
Provided herein is the ability for intravenous delivery of bacteria without the septic side-effects and for delivery of immune modulating proteins that are systemically toxic to be delivered directly to the tumor micro-environment without any systemic toxicity.
Absstract of: AU2022375120A1
An immunogenic gel compositions for oral administration and methods of immunizing an animal the methods including administering to the animal a therapeutically effective amount of an immunogenic gel composition comprising an antigen of an animal pathogen and a gel composition for oral administration.
Absstract of: US2024115686A1
Compositions and methods for eliciting an immune response in a subject (such as against Shigella) are provided. In examples, the compositions can include fusion proteins including one or more epitopes from Shigella or E. coli. In examples, the methods can include administering a disclosed fusion protein to a subject.
Absstract of: CA3218648A1
The invention refers to a method for simultaneous detection and quantification of Listeria monocytogenes, Salmonella spp. and Shiga toxin-producing Escherichia coli (STEC), from any kind of sample related to food production, including complex food matrices such as fish, meat, or fruit; or simple matrices such as water, or food contact surfaces. The method of invention allows specific quantification of the above-mentioned pathogens simultaneously thanks to specificity of designed primers for the qPCR reaction. It is also highly reliable because the method includes a system to adequately control the quantification of pathogens within the matrix. This system comprises the inoculation of samples with a known concentration of a transformed microorganism (host) carrying a chimeric sequence, acting as an internal control host for the whole process.
Absstract of: CA3219794A1
The present disclosure provides a method of treating or preventing symptoms of allergic rhinitis or chronic nasal congestion in a subject by administering to the subject an MPLA compound.
Absstract of: US2021347885A1
Synthetic binding agents for reducing the fraction of targets that can permeate through mucus and/or freely divide, and methods of reducing mucosal permeation and/or free division of a target using these synthetic binding agents.
Nº publicación: WO2024065274A1 04/04/2024
Applicant:
SYNBIO TECH INC [CN]
SYNBIO TECH INC
Absstract of: WO2024065274A1
Provided is a method against Salmonella typhimurium infection using a composition containing cultures of Lactobacillus rhamnosus LRH10 which is deposited at the Deutsche Sammlung Von Mikroorganismen und Zellkulturen (DSMZ) GmbH under an accession number DSM 32786, Lactobacillus paracasei LPC12 which is deposited at the DSMZ GmbH under an accession number DSM 32785, Lactobacillus fermentum LF26 which is deposited at the DSMZ GmbH under an accession number DSM 32784，Streptococcus thermophilus ST30 which is deposited at the DSMZ GmbH under an accession number DSM 32788, and Lactobacillus helveticus LH43 which is deposited at the DSMZ GmbH under an accession number DSM 32787.
BOPI
Electronic site
